Phase 1 Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People between the ages of 30 and 75 with type 2 diabetes
- People with a Body Mass Index (a measure of body weight relative to height) between 21 and 45
- People whose blood sugar control measure (HbA1c) falls between 7.0% and 11%
- People whose kidneys are working at a sufficient level, as measured by a test called eGFR being above 60 ml/min/1.73m²
- People whose blood pressure is at or below 160/90 mmHg
- People who are in generally good health, based on medical history, physical examination, and a range of standard tests including blood tests, heart tracing (EKG), thyroid hormone levels, and urine tests
- People whose weight has been stable (within 1.5 kg) over the last 3 months and who are not doing very intense exercise
- People managing their diabetes through diet alone, or with medications called Sulfonylureas, Metformin, or a combination of both
- People taking a medication called a GLP-1 receptor agonist, provided the dose has been stable for at least 3 months before joining the study
- People taking a medication called a DPP-4 inhibitor, provided the dose has been stable for at least 2 months before joining the study
- People who stopped taking an SGLT2 inhibitor at least 2 months before the screening visit
- People taking a statin (a cholesterol-lowering medication), provided the dose has been stable for at least 3 months
Who may not be able to join:
- People currently being treated with a class of diabetes medications called Thiazolidinediones (TZDs), or with insulin
- People taking other medications known to affect blood sugar levels, beyond those listed in the inclusion criteria
- People who have taken an SGLT2 inhibitor within the 2 months before their screening visit (confirm with trial site regarding whether stopping the medication early may allow eligibility to be reconsidered)
- People with advanced diabetes-related eye disease (proliferative retinopathy) or reduced kidney function (eGFR below 60)
- Women who are able to become pregnant, unless they are using an appropriate form of contraception
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ralph DeFronzo, MD, The University of Texas Health Science Center at San Antonio
Phone: 210-567-6691
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Endogenous Glucose Production (EGP)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.